Donald JD - Acer Therapeutics Chief Sec

ACERDelisted Stock  USD 0.84  0.02  2.33%   

Insider

Donald JD is Chief Sec of Acer Therapeutics
Age 69
Phone844 902 6100
Webhttps://www.acertx.com

Acer Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.6527) % which means that it has lost $0.6527 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.7299) %, meaning that it created substantial loss on money invested by shareholders. Acer Therapeutics' management efficiency ratios could be used to measure how well Acer Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Acer Therapeutics currently holds 11.86 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Acer Therapeutics has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Acer Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

James FosterVirax Biolabs Group
39
PharmD BCPSNeurobo Pharmaceuticals
N/A
Frank KondradNeurobo Pharmaceuticals
N/A
Philip AinslieLexaria Bioscience Corp
N/A
Edward DVMSAB Biotherapeutics
N/A
David BrionesHoth Therapeutics
48
Vanessa CarleLexaria Bioscience Corp
N/A
Daniel SchneidermanPasithea Therapeutics Corp
46
Pablo MDZyVersa Therapeutics
N/A
Yassine BendiabdallahPasithea Therapeutics Corp
40
Ben MDNeurobo Pharmaceuticals
68
Pr SorekBiomx Inc
N/A
Tomasz GeorgeVirax Biolabs Group
40
Xiaoqin MDAvenue Therapeutics
49
MD BAPasithea Therapeutics Corp
76
Christopher BunkaLexaria Bioscience Corp
62
Christine MBASAB Biotherapeutics
68
Tiago MarquesPasithea Therapeutics Corp
47
CPA CMALexaria Bioscience Corp
63
Eddie SullivanSAB Biotherapeutics
58
Karen CashmereZyVersa Therapeutics
72
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts. Acer Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. Acer Therapeutics (ACER) is traded on NASDAQ Exchange in USA and employs 30 people.

Management Performance

Acer Therapeutics Leadership Team

Elected by the shareholders, the Acer Therapeutics' board of directors comprises two types of representatives: Acer Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acer. The board's role is to monitor Acer Therapeutics' management team and ensure that shareholders' interests are well served. Acer Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acer Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jefferson Davis, Chief Officer
Jason CPA, VP Controller
John Klopp, Vice President - Manufacturing
Donald JD, Chief Sec
Bernie Paul, Chief Officer
Harry Palmin, Chief Officer
Matthew Seibt, Chief Officer
Tanya Hayden, Chief Officer
MD FFPM, Chief Officer
Christopher Schelling, President CEO, Director

Acer Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Acer Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Acer Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acer Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acer Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Acer Stock

  0.53MMM 3M Company Fiscal Year End 28th of January 2025 PairCorr
  0.42GE GE Aerospace Sell-off TrendPairCorr
  0.37HD Home DepotPairCorr
  0.34VZ Verizon Communications Fiscal Year End 28th of January 2025 PairCorr
The ability to find closely correlated positions to Acer Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acer Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acer Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acer Therapeutics to buy it.
The correlation of Acer Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acer Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acer Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acer Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Consideration for investing in Acer Stock

If you are still planning to invest in Acer Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acer Therapeutics' history and understand the potential risks before investing.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Money Managers
Screen money managers from public funds and ETFs managed around the world
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Bonds Directory
Find actively traded corporate debentures issued by US companies
Stocks Directory
Find actively traded stocks across global markets
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges